What Is AOD-9604?

AOD-9604 is a synthetic peptide consisting of amino acids 177 through 191 of the human growth hormone (HGH) sequence, with a tyrosine residue added to the N-terminus to improve stability. The name stands for Anti-Obesity Drug 9604, reflecting the original research goal at Monash University in Australia during the 1990s. Scientists there were trying to isolate the portion of HGH responsible for fat breakdown while leaving behind the portions that drive insulin resistance and IGF-1 elevation.

Full-length HGH has a well-documented lipolytic effect, meaning it promotes the release of stored fat for energy. The problem with using HGH itself for weight management is that it also raises IGF-1, which carries its own set of metabolic and safety concerns. The hypothesis behind AOD-9604 was that the C-terminal fragment could retain the lipolytic signaling without those downstream effects. That hypothesis has been tested in cell cultures, rodent models, and a small number of human trials, with mixed results across those tiers.

Structurally, AOD-9604 is a 16-amino-acid peptide. It is small enough to be studied in oral formulations, which is unusual for peptides, since most are broken down in the gastrointestinal tract before reaching systemic circulation. Some of the human trials discussed below used oral delivery specifically because of this property.

How Does AOD-9604 Work at the Cellular Level?

In preclinical research, AOD-9604 has been shown to stimulate lipolysis, the process by which fat cells break down stored triglycerides into free fatty acids. Studies in rodent fat cell preparations found that the peptide activates beta-3 adrenergic receptors and may also interact with the same receptor pathway that full-length HGH uses to signal fat metabolism. A 2000 paper by Heffernan and colleagues published in the Journal of Endocrinology reported that AOD-9604 reduced body fat in obese mice without measurably altering blood glucose or IGF-1 levels.

In vitro work has also examined AOD-9604 in the context of cartilage and bone. A series of studies from researchers at Nucleus Network and Paradigm Biopharmaceuticals, published between 2014 and 2019, looked at whether the peptide could stimulate proteoglycan synthesis in chondrocytes, the cells that make up cartilage. Those cell-culture and rodent experiments suggested the peptide may support cartilage matrix production, which is what led to later osteoarthritis-focused clinical trials.

It is worth being clear about what in vitro and animal data can and cannot tell us. A compound that reduces fat in obese mice or stimulates cartilage cells in a dish has cleared a very early bar. Most compounds that show promise at this stage do not go on to demonstrate the same effects in human trials at the same magnitude. That context matters when reading the broader claims circulating about this peptide online.

What Did Human Trials Find?

The most substantial human trial program for AOD-9604 was conducted by Metabolic Pharmaceuticals, the Australian company that licensed the compound from Monash University. They ran a series of Phase 2 randomized controlled trials in the early 2000s examining oral AOD-9604 for obesity. The largest of these, a multicenter trial published around 2004 and involving several hundred overweight adults, tested multiple doses over 12 weeks. Participants in the higher-dose arms showed modest reductions in body weight compared to placebo, but the effect sizes were small and the program did not advance to Phase 3. Metabolic Pharmaceuticals publicly reported that the Phase 2b results were not sufficient to support a regulatory submission for an obesity indication.

More recently, Paradigm Biopharmaceuticals has been running clinical trials examining AOD-9604 for knee osteoarthritis, delivered by intra-articular injection rather than orally. A Phase 2 trial registered on ClinicalTrials.gov (NCT02795585) enrolled patients with mild to moderate knee osteoarthritis to evaluate safety and symptom outcomes. Results from this program have been reported in investor communications and conference presentations, with the company noting signals of symptom improvement in some subgroups, though peer-reviewed publication of full trial data has been limited as of early 2025.

There are no completed Phase 3 human trials for AOD-9604 in any indication, and no regulatory body, including the FDA or the Therapeutic Goods Administration in Australia, has approved it as a drug. The human evidence base is therefore limited to Phase 1 and Phase 2 data, which is useful for understanding safety signals and early efficacy signals but is not sufficient to establish that a compound works for a given condition.

Regulatory Status and the Research-Chemical Market

AOD-9604 has no approved pharmaceutical form in the United States, Australia, or the European Union. It is not equivalent to any branded prescription drug. This distinguishes it from compounds like semaglutide, where the approved drugs Wegovy and Ozempic exist as specific regulated products, and the peptide sold in research markets is a separate, unapproved substance.

In the United States, AOD-9604 is sold by research chemical suppliers as a compound intended for laboratory use only. The FDA has not approved it for human use, and it does not appear on the FDA's list of bulk drug substances that may be used in compounding. In 2016, the FDA issued guidance clarifying that AOD-9604 is not an approved active pharmaceutical ingredient and cannot be used in compounded preparations for human administration. That guidance has not changed.

The World Anti-Doping Agency (WADA) includes AOD-9604 on its prohibited list under the category of peptide hormones, growth factors, and related substances. Athletes subject to anti-doping rules should be aware that the compound is banned in competition and out of competition under current WADA code.

Honest Limits of the Evidence

The evidence record for AOD-9604 is thinner than the volume of online discussion about it might suggest. The strongest data comes from rodent studies, which consistently show lipolytic effects. The human obesity trial program produced modest, inconsistent results and was discontinued before reaching Phase 3. The osteoarthritis program is ongoing but has not yet produced peer-reviewed Phase 3 data. In vitro cartilage research is promising at a mechanistic level but remains preclinical.

One specific gap worth noting is the absence of long-term human safety data. The Phase 2 obesity trials ran for 12 weeks, which is a short window for assessing chronic effects. The intra-articular osteoarthritis trials involve a different route of administration and a different patient population, so safety data from one program does not automatically transfer to the other.

Researchers and readers should also be cautious about the quality of AOD-9604 available outside of clinical trial settings. Peptides sold through research chemical suppliers are not subject to pharmaceutical-grade manufacturing standards, meaning purity, potency, and sterility can vary significantly between batches and suppliers. This is a practical limitation that affects any attempt to draw conclusions from anecdotal reports.

Frequently asked questions

Is AOD-9604 the same as HGH?

No. AOD-9604 is a 16-amino-acid fragment taken from the C-terminal end of the 191-amino-acid human growth hormone molecule. Full-length HGH stimulates IGF-1 production and has broad anabolic effects. AOD-9604 was specifically designed to isolate the lipolytic portion of HGH signaling. Preclinical studies suggest it does not raise IGF-1 at the doses tested, though this has only been confirmed in short-term human trials.

Did AOD-9604 ever receive FDA approval?

No. AOD-9604 has never been approved by the FDA for any indication. The obesity drug program run by Metabolic Pharmaceuticals in the early 2000s did not advance past Phase 2. In 2016, the FDA clarified that AOD-9604 is not an approved active pharmaceutical ingredient and cannot be used in compounded preparations for human use in the United States.

What is Paradigm Biopharmaceuticals studying AOD-9604 for?

Paradigm Biopharmaceuticals, an Australian company, has been running clinical trials examining AOD-9604 delivered by intra-articular injection for knee osteoarthritis. Their Phase 2 trial (NCT02795585) enrolled patients with mild to moderate knee osteoarthritis to assess safety and symptom outcomes. As of early 2025, this program has not produced a peer-reviewed Phase 3 publication, and the compound remains unapproved.

Sources

  1. Heffernan et al., 2000, Journal of Endocrinology Rodent study on AOD-9604 lipolytic effects
  2. Ng et al., 2000, Journal of Endocrinology AOD-9604 fat reduction without IGF-1 elevation
  3. ClinicalTrials.gov, NCT02795585, Paradigm Biopharmaceuticals Phase 2 osteoarthritis trial registration

Educational and informational content only. This is not medical advice, diagnosis, or treatment. The compounds discussed are research compounds that are not approved for human use outside specific prescribed contexts. Always consult a qualified, licensed clinician before making any health decision.